Therapy insight: Cirrhotic cardiomyopathy

Area of Science:

• Cardiology
• Hepatology
• Internal Medicine

Background:

• Liver cirrhosis is linked to significant cardiovascular issues, including a hyperdynamic circulatory state.
• Patients with cirrhosis exhibit impaired cardiac function, characterized by reduced contractile responses and electrophysiological changes.
• These cardiac abnormalities collectively define cirrhotic cardiomyopathy, impacting patient prognosis.

Purpose of the Study:

• To review the clinical features, diagnostic criteria, pathogenesis, and treatment of cirrhotic cardiomyopathy.
• To highlight the role of cirrhotic cardiomyopathy in cardiac dysfunction and heart failure post-liver transplantation and surgery.
• To discuss the contribution of depressed cardiac contractility to hepatorenal syndrome.

Main Methods:

• This is a review article, synthesizing existing literature.
• The review discusses clinical observations and proposed pathogenic mechanisms.
• Diagnostic criteria and therapeutic strategies are examined based on current evidence.

Main Results:

• Cirrhotic cardiomyopathy presents with hyperdynamic circulation, abnormal systolic and diastolic function, and electrophysiological disturbances like QT prolongation.
• Cardiac dysfunction in cirrhosis contributes to adverse outcomes in liver transplantation, major surgery, and hepatorenal syndrome.
• Pathogenesis involves cardiomyocyte membrane changes, altered beta-adrenergic signaling, and increased cyclic GMP activity.

Conclusions:

• Cirrhotic cardiomyopathy is a distinct clinical entity in liver cirrhosis patients.
• Understanding its mechanisms is crucial for improving management and patient outcomes.
• Further research into targeted therapies for cirrhotic cardiomyopathy is warranted.